

TABLE OF CONTENTS

Book 1

Preface	i
Editorial Board	ii
Book 1 Panel	iii
Disclosure of Potential Conflicts of Interest	vii
Continuing Education and Program Evaluation Instructions	x
Roles of ACCP and BPS	xiii

Cardiology I

HYPERTENSION: EVIDENCE-BASED UPDATES AND CLINICAL CONTROVERSIES	
Learning Objectives	1
Introduction	1
Overview	1
Definitions	1
Diagnosis	1
Quality Patient Care—National Treatment Guidelines	2
JNC 7 Goals and Treatment Recommendations	2
Therapeutic Goals	2
Pharmacotherapy Recommendations	2
Most Patients Without Compelling Indications	2
Patients With Compelling Indications	3
Role of Lifestyle Modifications	3
Treatment Plans	3
Monotherapy and Combination Therapy Approaches	3
Evidence-Based Update and Controversies	4
Evolution of Long-Term Outcome Trials	4
Historical End Points Versus Combined Cardiovascular Events	4

Use of Combination Regimens	5
Meta-Analysis of Blood Pressure-Lowering Trials	6
First-Line Pharmacotherapy	6
Thiazide-Type Diuretics Versus Other Drugs	7
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial	7
ALLHAT Subgroup Analyses in Special Populations	7
ALLHAT Subgroup: Blacks Versus Non-Blacks	7
ALLHAT Subgroup: Diabetes, Impaired Fasting Glucose, and Normoglycemia	7
ALLHAT Subgroup: Reduced Glomerular Filtration Rate	8
Anglo-Scandinavian Cardiac Outcomes Trial	8
Women's Health Initiative Observational Study	8
Calcium Channel Blocker Versus Angiotensin Receptor Blocker	8
Treatment of Hypertension With Comorbid Compelling Indications	9
Coronary Disease: Chronic Stable Angina	9
β -Blocker Versus Non-Dihydropyridine CCB	9
β -Blocker Versus Dihydropyridine CCB	9
ACE Inhibitor Therapy	9
Recurrent Stroke Prevention	10
Chronic Kidney Disease	10
Other Clinical Controversies	10
Hydrochlorothiazide Versus Chlorthalidone	10
β -Blocker Therapy	11
Atenolol Versus Other β -Blockers	11
Carvedilol Versus Metoprolol in Type 2 Diabetes	11
The Elderly Population	11
Conclusion	12
Annotated Bibliography	12
Self-Assessment Questions	17
DYSLIPIDEMIAS: THERAPEUTIC ADVANCES	
Learning Objectives	21
Introduction	21

Adult Treatment Panel III Update 2004 21
 Therapy Goals 21
 Treatment Approach 22
 Pathophysiology 22
 Acute Coronary Syndromes 22
 Statins and ACS 22
 Novel and Emerging Risk Factors 23
 C-Reactive Protein 23
 Apolipoprotein B 24
 Quality Patient Care 24
 Pharmacotherapy 24
 Therapeutic Lifestyle Change 24
 Nonprescription Products 24
 Treatment Plan 25
 Approach to Dyslipidemia by Particle Type 25
 Low-Density Lipoprotein 25
 Rosuvastatin 25
 Intestinal-Acting Drugs 26
 Triglycerides 26
 Fibrates 26
 Fish Oil 26
 High-Density Lipoprotein 26
 Statins and Fibrates 27
 Niacin 27
 Novel HDL Therapies 28
 Mixed Dyslipidemia 28
 Metabolic Syndrome Dyslipidemia Treatment 28
 Human Immunodeficiency Virus Lipodystrophy 28
 Special Populations 29
 Diabetes 29
 Peroxisome Proliferator-Activated Receptor
 Agonists 29
 Statins in Diabetes 29
 Elderly 29
 How Old is Too Old? 29
 Stroke Prevention 29
 Pediatrics 30
 Childhood Obesity and CHD 30
 Treatment of Children with Dyslipidemia 30
 Quality Patient Care 30
 Cardiovascular Performance Measures 30
 Pharmacist-Managed Programs 30
 Compliance Interventions 30
 Pharmacist-Managed Lipid Clinics 30
 Conclusion 30
 Annotated Bibliography 31
Self-Assessment Questions 35

DRUG-INDUCED CARDIAC DISEASES
 Learning Objectives 39
 Introduction 39
 Drugs That Induce Cardiac Arrhythmias 39
 The Electrocardiogram and Arrhythmias 39
 PR Intervals and Their Prolongation 39
 Negative Dromotropic Drugs and Heart Block 40
 Management of Drug-Induced Heart Block 40

Corrected QT Intervals and Their Prolongation 41
 Drugs That Prolong the QTc Interval and the
 Transmural Dispersion of Repolarization 42
 Drug Interactions and the QTc Interval 44
 Therapy for Drug-Induced Torsade de Pointes 45
 Drug-Induced Ischemic Heart Disease 45
 Cyclooxygenase-2 Inhibition and Coronary Disease
 Risk 45
 Mechanism of Cardiovascular Risk With COX-2
 Inhibition 46
 Platelet Aggregation Effects 46
 Collateral Circulation Effects 46
 Ischemic Preconditioning 47
 Heart-Friendly Pain Management/Pharmacist's
 Role 47
 Cocaine-Induced Myocardial Infarction 48
 Mechanism of Cocaine-Induced Myocardial
 Infarction 48
 Myocardial Oxygen Demand 48
 Coronary Artery Vasoconstriction 48
 Effect on Thrombus Formation 48
 Therapy for Cocaine-Induced Myocardial
 Infarction 48
 Role of the Pharmacist in Cocaine-Induced
 Myocardial Infarction 48
 Conclusion 49
 Annotated Bibliography 49
Self-Assessment Questions 53

Cardiology II

ACUTE CORONARY SYNDROMES: EVOLVING PRACTICES
 Learning Objectives 59
 Introduction 59
 Pathophysiology 59
 Plaque Rupture, Thrombosis, and Risk
 Stratification 59
 Mortality 60
 Novel Markers of Risk 60
 High-Sensitivity C-Reactive Protein 61
 Lipoprotein Phospholipase A₂ 61
 Cystatin C 62
 Goals of Therapy 63
 Quality Patient Care 63
 Treatment Plan 63
 ST-Segment Elevation ACS Algorithm 63
 Non-ST-Segment Elevation ACS Algorithm 63
 Beyond Primary Percutaneous Coronary
 Intervention: Role of Hospital Transfer 69
 Pharmacotherapy 70
 LMWHs Versus UFH in Combination with Aspirin
 and Fibrinolytic Drugs for ST-Segment
 Elevation ACS 70
 New Role for Clopidogrel in ST-Segment
 Elevation ACS 71

Early β -Blockade in ST-Segment Elevation ACS: Intravenous Versus Oral Therapy	72	Antilymphocyte Antibodies	104
Newer Anticoagulant Drugs for Acute Coronary Syndromes	72	Interleukin-2 Receptor Blockade	104
Enoxaparin	72	Candidates for Therapy	105
Fondaparinux	72	Management After Hospital Discharge	105
Bivalirudin	73	Maintenance Immunosuppression Strategies	105
Quality Improvement	74	Rejection	106
Update in Quality Performance Measures	74	Types of Rejection	106
The Role of Registries	75	Treatment Strategies	107
Practice Guideline Implementation	75	Coronary Allograft Vasculopathy	108
The Role of the Pharmacist	75	Diagnosis	108
Conclusion	76	Clinical Presentation	108
Annotated Bibliography	76	Angiography	109
Self-Assessment Questions	81	Intravascular Ultrasound	109
ACUTE HEART FAILURE AND CARIOGENIC SHOCK		Prevention	109
Learning Objectives	85	Risk Factor Modification	109
Introduction	85	Anticytomegalovirus Therapy	109
Pathophysiology	85	Folic Acid	109
Definitions	85	Vitamins C and E	109
Underlying Pathophysiology	85	Immunosuppressant Regimens	109
Etiology	86	Mycophenolate Mofetil	110
Clinical Characteristics	87	Target of Rapamycin Inhibitors	110
Diagnosis	88	Treatment	110
Prognosis	88	Long-Term Complications	110
Therapeutic Goals	89	Hypertension	110
Quality Patient Care	89	β -Blockers and Thiazide Diuretics	111
Pharmacotherapy	89	Calcium Channel Blockers	111
Diuretic Therapy	89	Dyslipidemia	111
Vasodilators	90	Statins	111
Inotropes	90	Fibric Acid Derivatives	112
Calcium Sensitizers	91	Omega-3 Fatty Acids (Fish Oil)	112
Nonpharmacological Therapy	92	Other Drugs	112
Devices	92	Outcome and Survival	112
Ultrafiltration	92	Mortality	112
Treatment Plan	92	Quality of Life	113
Cardiogenic Shock Following AMI	92	Costs	113
Monitoring	93	Role of the Pharmacist	113
Patient Education	93	Future Directions	113
Quality Improvement	93	Conclusion	114
Conclusion	94	Annotated Bibliography	114
Annotated Bibliography	94	Self-Assessment Questions	117
Self-Assessment Questions	97	ISCHEMIC STROKE	
CARDIAC TRANSPLANTATION		Learning Objectives	121
Learning Objectives	101	Introduction	121
Introduction: Brief Historical Perspective	101	Epidemiology	121
Recipient Evaluation and Selection	101	Incidence and Economic Impact	121
Preoperative Management	102	Risk Factors	122
Mechanical Circulatory Support Strategies	102	Classification and Causes	123
Pharmacological Support Strategies	102	Pathophysiology	124
Postoperative Management	103	Mechanisms of Injury	124
Management During Hospitalization	103	Primary Injury	124
Calcineurin Inhibitor-Based Regimens	103	Secondary Injury	124
Antibody Induction	104	Drug-Induced Stroke	124
		Diagnosis and Clinical Characteristics	125
		Prognosis and Complications	125
		Pharmacotherapy	126

Acute Management	126
Reperfusion Therapy	127
Rationale for Use	127
Efficacy and Therapeutic Role	127
Intravenous Thrombolysis	127
Intra-Arterial Thrombolysis	127
Complications and Cost-Effectiveness	127
Antithrombotic Therapy	128
Rationale to Use	128
Anticoagulation Drugs	128
Antiplatelet Drugs	128
Antihypertensive Therapy	128
Rationale to Use	128
Antihypertensive Drugs	128
Stroke Prevention	129
Anticoagulation Therapy	129
Antiplatelet Therapy	130
Combination Antiplatelet Therapy	130
Antihypertensive Therapy	130
Statin Therapy	130
Future Therapy	130
Vascular Protection	130
Statins	131
ACE Inhibitors and ARBs	131
Other Vascular Protectants	131
Neuroprotective Therapy	131
Magnesium Therapy	131
Hypothermia Therapy	131
Other Neuroprotectants	131
Quality Patient Care	132
Public Awareness and Pre-Hospital Care	132
Pharmacist Role in Management and Prevention	132
Summary	133
Annotated Bibliography	133
Self-Assessment Questions	137

Cardiology III

CHRONIC STABLE ANGINA: MANAGEMENT AND PREVENTION OF FUTURE CARDIOVASCULAR EVENTS	
Learning Objectives	143
Introduction	143
Epidemiology	143
Definitions	143
Pathophysiology	144
Clinical Evaluation	145
Clinical Presentation	146
Diagnostic Tests	146
Treatment Options for Chronic Stable Angina	146
Goals of Therapy	146
Nonpharmacological Therapy	146
Risk Factor Modification	146

Lifestyle Modifications	147
Pharmacological Therapy	147
Anti-Ischemic Drugs	147
β -Blockers	148
Calcium Channel Blockers	148
Short-Acting and Long-Acting Nitrates	148
Ranolazine	148
Vasculo-Protective Drugs	149
Antithrombotic Therapy	149
ACE Inhibitors	150
Revascularization Therapy	150
Percutaneous Coronary Intervention	151
Therapeutic Approach to the Management of Patients With Chronic Stable Angina	153
Patient Education	154
Quality Improvement	154
Conclusion	154
Annotated Bibliography	154
Self-Assessment Questions	157

CHRONIC HEART FAILURE MANAGEMENT

Learning Objectives	161
Introduction	161
Overview	161
Classification System	161
Epidemiology	162
Primary Pharmacological Therapy	163
Diuretics	163
Angiotensin-Converting Enzyme Inhibitors	163
β -Blocking Drugs	164
Aldosterone Antagonists	165
Digoxin	165
Alternative Drugs	166
Angiotensin Receptor Blockers	166
Isosorbide and Hydralazine	167
Adjunctive Therapy	167
Anticoagulation	167
Antiarrhythmic Drugs	167
Outpatient Inotrope and Vasodilator Therapy	168
Outpatient Inotropic Therapy	168
Outpatient Nesiritide	168
Nonpharmacological Therapy	168
Implantable Cardioverter Defibrillators	168
Cardiac Resynchronization	169
Concomitant Drugs and Impact on the Disease	170
Lifestyle Modification and Patient Education	170
Multidisciplinary Care and the Role of the Pharmacist	171
Additional Therapeutic Considerations	171
Anemia	171
Conclusion	172
Annotated Bibliography	172
Self-Assessment Questions	175

ARRHYTHMIA MANAGEMENT: AN EVIDENCE-BASED UPDATE

Learning Objectives179

Introduction179

Atrial Fibrillation179

 Pathophysiology179

 Etiology180

 Epidemiology181

 Prognosis181

 Therapeutic Goals/Outcomes181

 Quality Patient Care181

 Pharmacological Therapy181

 Management of Postoperative Atrial Fibrillation181

 Chronic Management of Atrial Fibrillation183

 Update on Recent Clinical Trials183

 Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers183

 Omega-3 Fatty Acids183

 Results of Sotalol Amiodarone Atrial Fibrillation Efficacy Trial184

 Update on Rate Versus Rhythm Control Controversy184

 Recent Clinical Trials184

 Nonpharmacological Therapy185

 Treatment Plan185

 Management of Postoperative Atrial Fibrillation185

 Management of Atrial Fibrillation186

 Overview of Updated Treatment Guidelines186

 Ventricular Rate Control186

 Restoring/Maintaining Sinus Rhythm186

 Prevention of Thromboembolic Events188

 Monitoring189

 Ventricular Arrhythmias/Asystole/Pulseless Electrical Activity192

 Epidemiology192

 Therapeutic Goals/Outcomes192

 Quality Patient Care192

 Pharmacological Therapy192

 Acute Management of Ventricular Arrhythmias/Asystole/Pulseless Electrical Activity192

 Chronic Management of Ventricular Arrhythmias192

 Update on Recent Clinical Trials192

 Omega-3 Fatty Acids192

 Prevention of Implantable Cardioverter Defibrillator Shocks193

 Nonpharmacological Therapy194

 Treatment Plan194

 Management of Cardiac Arrest194

 Pulseless Ventricular Tachycardia/Ventricular Fibrillation194

 Asystole and Pulseless Electrical Activity196

 Chronic Management of Ventricular Arrhythmias197

 Primary Prevention of Sudden Cardiac Death197

 Conclusion197

 Annotated Bibliography197

Self-Assessment Questions201

PERIPHERAL ARTERIAL DISEASE

Learning Objectives205

Introduction205

Pathophysiology205

 Definitions205

 Etiology205

 Clinical Evaluation206

 PAD Classification206

 Diagnosis206

 Epidemiology208

 Prognosis208

 Exercise Therapy208

 Pharmacotherapy of PAD209

 Antiplatelet Therapy209

 Aspirin and Dipyridamole209

 Thienopyridines209

 Anticoagulants210

 Intermittent Claudication Therapy210

 Vasodilators210

 Cilostazol210

 Pentoxifylline211

 Fibrinolytic Drugs211

 Clinical Use211

 Fibrinolytic Drugs Versus Surgery212

 Therapeutic Approach to Managing PAD212

 Therapy Goals212

 Practice Guidelines212

 Risk Factor Modification213

 Smoking213

 Hypertension213

 Diabetes Mellitus213

 Hyperlipidemia214

 β-Blocker Controversy214

 Asymptomatic PAD214

 Intermittent Claudication215

 Acute Limb Ischemia216

 Initial Therapy216

 Fibrinolytic Drugs216

 Percutaneous Approach217

 Surgical Approach217

 Investigational Pharmacotherapy217

 Nutritional Supplements217

 L-Arginine217

 Propionyl-L-Carnitine217

 Ginkgo Biloba218

 Patient Education218

 Quality Improvement218

 Documentation218

 Conclusion218

 Annotated Bibliography219

Self-Assessment Questions223